AngioDynamics ANGO Accounts Receivable, Credit Loss Expense (Reversal)
Accounts Receivable, Credit Loss Expense (Reversal) at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.
The official record: AngioDynamics’s 10-Q, filed April 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about AngioDynamics's accounts receivable, credit loss expense (reversal).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AngioDynamics's accounts receivable, credit loss expense (reversal)?
- AngioDynamics (ANGO) reported accounts receivable, credit loss expense (reversal) of $317K in Q4 2025.
- How has AngioDynamics's accounts receivable, credit loss expense (reversal) changed year-over-year?
- AngioDynamics's accounts receivable, credit loss expense (reversal) increased by 123.2% year-over-year, from $142K to $317K.
- What is the long-term trend for AngioDynamics's accounts receivable, credit loss expense (reversal)?
- Over 3 years (2022 to 2025), AngioDynamics's accounts receivable, credit loss expense (reversal) has grown at a 80.9% compound annual growth rate (CAGR), from $118K to $699K.